Score Breakdown
Offering Ability
40
Cash Runway
25
Float Risk
37
Warrant Exposure
40
Convertible Debt
85
Dilution Forecast
⛈️
Warning
High probability of dilution event
model est. 46%
🔁 Convertible Conversion
model 60%
• Major convertible overhang: 161% potential dilution
• Convertible risk score very high (85/100)
🔄 Reverse Split
model est. 55%
• 50-day avg $0.62 below $1 exchange minimum
Market Data
Market Cap$27.81M
Shares Outstanding40.85M
Float27.26M
Cash$59.30M
Debt$159.0K
Short InterestN/A
Institutional Holdings
QoQ: ↑ 17.8% shares (2026Q1 vs prior)
14 institutional holders · 9.31M shares
#1
M&G PLC
5.20M shares
#2
HSG Holding Ltd
1.42M shares
#3
GLR Partners, LLC
1.24M shares
+ 11 more holders Sign up free to view →
Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.
Short Interest
Short Interest45.9K
Days to Cover1.8
% of Float0.2%
FINRA data as of Jul 31, 2026
Recent SEC Activity
xbrl
XBRL CONVERTIBLE
2020-12-31
Full SEC filing analysis available with free account →
Recent News
No recent news
Factual BRNS Dilution Snapshot
Barinthus Biotherapeutics plc (BRNS) has a DilutionScore of 42/100, rated Medium dilution risk. Score date: August 28, 2026.
- Recent SEC activity tracked for BRNS: xbrl on 2020-12-31.
This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.
Related Stocks — MEDIUM Risk
Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles: